Trial Profile

Phase I study on antiangiogenic vaccine therapy using epitope peptide derived from VEGFR1 [vascular endothelial growth factor receptor 1] and VEGFR2 with gemcitabine in treating patients with unresectable, recurrent, or metastatic pancreatic cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Mar 2013 Biomarkers information updated
13 Mar 2013 Planned end date changed from 1 May 2009 to 1 Mar 2013 as reported by ClinicalTrials.gov.
04 Apr 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com